Name: Vinpocetine
Price: 196.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Vinpocetine is a selective inhibitor of cyclic GMP phosphodiesterase (PDE) with a Ki value of 14±2μM [1].Vinpocetine has been reported to have a selective and noncompetitive inhibition of Ca2+ PDE and thus regulate cyclic GMP levels in smooth muscle. In addition, vinpocetine has been revealed to inhibit the activities of three resolvable PDE in the cytosol of rat aorta with Ki values of 14±2μM, >1000μM and >1000μM for Ca2+ PDE(+)CaM, cGMP PDE and cAMP PDE, respectively. Apart from these, vinpocetine has shown the potent inhibition of 5-HT-induced contractions in endothelium-intact rat aorta with an EC50 value of 1μM [1].
    
    [1] Souness JE1, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989 Nov;98(3):725-34.
- Properties
  - Alternative Name
    
    (41S,13aS)-ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
    
    CAS Number
    
    42971-09-5
    
    Molecular Formula
    
    C22H26N2O2
    
    Molecular Weight
    
    350.45
    
    Appearance
    
    A solid
    
    Purity
    
    99.08%
    
    Solubility
    
    ≥2.59 mg/mL in H2O with gentle warming and ultrasonic; ≥2.99 mg/mL in EtOH with ultrasonic; ≥5.83 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Zhu M, Liu H, et al. "Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss." Biomed Pharmacother. 2019 Dec 14;123:109769. PMID:31846839

Vinpocetine

Vinpocetine

Background

We Also Recommend

A-803467

Ibutilide Fumarate